GRI Bio (GRI) News Today $2.06 -0.14 (-6.36%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$2.06 0.00 (-0.24%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock GRI Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period GRI Bio to Present at A.G.P.’s Annual Healthcare Company ShowcaseMay 18, 2026 | markets.businessinsider.comGRI Bio to Present at A.G.P.'s Annual Healthcare Company ShowcaseMay 18, 2026 | globenewswire.comGRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued ...May 14, 2026 | markets.businessinsider.comGRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating PipelineMay 14, 2026 | globenewswire.comGRI Bio (GRI) Expected to Announce Quarterly Earnings on ThursdayMay 14, 2026 | americanbankingnews.comGRI Bio (GRI) price target decreased by 75.16% to 163.20April 9, 2026 | msn.comGRI Springs on UAE PatentApril 9, 2026 | baystreet.caGRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory ConditionsApril 8, 2026 | globenewswire.comGRI Bio, Inc. Discusses Positive Phase 2a Data in Idiopathic Pulmonary Fibrosis During Virtual Investor SegmentFebruary 17, 2026 | quiverquant.comQGRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” SegmentFebruary 17, 2026 | globenewswire.comGRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialFebruary 5, 2026 | globenewswire.comGRI Bio, Inc.: GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent HighlightsFebruary 4, 2026 | finanznachrichten.deGRI Bio (GRI) price target increased by 2,700.00% to 656.88February 4, 2026 | msn.comGRI Bio, Inc. Reports Strong Cash Position and Positive Phase 2a Results for GRI-0621 in Pulmonary FibrosisFebruary 4, 2026 | quiverquant.comQGRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent HighlightsFebruary 4, 2026 | globenewswire.comGRI Bio Expands At-The-Market Equity Offering CapacityJanuary 30, 2026 | tipranks.comGRI Bio, Inc.: GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPFJanuary 29, 2026 | finanznachrichten.deGRI Bio reports positive study results for chronic lung disease, but stock slumps 20% — what happened?January 29, 2026 | msn.comGRI Bio stock soars after gene data shows IPF drug targets disease driversJanuary 28, 2026 | in.investing.comGRI Bio, Inc. Reports Positive Phase 2a Results for GRI-0621 as Disease-Modifying Therapy in Idiopathic Pulmonary FibrosisJanuary 28, 2026 | quiverquant.comQGRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPFJanuary 28, 2026 | globenewswire.comGRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound StructuresJanuary 26, 2026 | markets.businessinsider.comGRI Bio stock falls after announcing 1-for-28 reverse splitJanuary 21, 2026 | in.investing.comGRI Bio Announces Reverse Stock SplitJanuary 21, 2026 | globenewswire.comGRI Bio Regains Conditional Compliance With Nasdaq Listing RequirementsJanuary 16, 2026 | tipranks.comGRI Bio Shareholders Authorize Reverse Stock Split PlanJanuary 15, 2026 | tipranks.comGRI Bio Expands At-The-Market Equity Offering CapacityJanuary 9, 2026 | tipranks.comGRI Bio stock rises on positive Phase 2a immune data for IPF treatmentJanuary 8, 2026 | za.investing.comGRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621January 8, 2026 | finance.yahoo.comGRI Bio (GRI) price target decreased by 77.56% to 23.46December 22, 2025 | msn.comGRI Bio, Inc. Closes Public Offering, Raising Approximately $8 Million in Funds for Product DevelopmentDecember 12, 2025 | quiverquant.comQGRI Bio Announces Closing of $8.0 Million Public OfferingDecember 12, 2025 | globenewswire.comGRI Bio Launches $6.7 Million Public OfferingDecember 12, 2025 | tipranks.comGRI Bio prices 10.67M shares at 75C in public offeringDecember 12, 2025 | msn.comGRI Bio’s tazarotene achieves Phase IIa IPF successDecember 12, 2025 | msn.comGRI Bio Announces Pricing of $8,000,000 Million Public OfferingDecember 11, 2025 | globenewswire.comGRI Bio announces positive Phase 2a trial resultsDecember 11, 2025 | msn.comGRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpointsDecember 11, 2025 | msn.comGRI Bio, Inc. Reports Positive Phase 2a Results for GRI-0621 in Treating Idiopathic Pulmonary FibrosisDecember 10, 2025 | quiverquant.comQGRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)December 10, 2025 | globenewswire.comAscendiant Capital maintains GRI Bio (GRI) buy recommendationDecember 8, 2025 | msn.comGRI Bio reports positive phase 2a trial resultsDecember 8, 2025 | msn.comGRI Bio reports six-week lung function data in Phase 2a study of GRI-0621September 12, 2025 | msn.comGRI Bio, Inc. Reports No Decline in Lung Function at 6-Week Interim Analysis of Phase 2a Study for GRI-0621 in Idiopathic Pulmonary FibrosisSeptember 11, 2025 | quiverquant.comQGRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)September 11, 2025 | globenewswire.comGRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | markets.businessinsider.comGRI Bio, Inc. CEO Dr. Marc Hertz to Present at H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025September 3, 2025 | quiverquant.comQGRI Bio Stockholders Approve Equity Plan AmendmentAugust 14, 2025 | msn.comGRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | globenewswire.comGRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)July 31, 2025 | finance.yahoo.com Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRI Media Mentions By Week GRI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GRI News Sentiment▼-0.200.45▲Average Medical News Sentiment GRI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GRI Articles This Week▼82▲GRI Articles Average Week Get the Latest News and Ratings for GRI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for GRI Bio and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MBRX News CLRB News BLRX News AIMD News HOTH News PHIO News GTBP News BCDA News APRE News IMNN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GRI) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
